Next 10 |
2024-03-28 07:22:06 ET More on CASI Pharmaceuticals CASI stock rises on positive interim data from early stage trial for its NHL treatment in China Seeking Alpha’s Quant Rating on CASI Pharmaceuticals Historical earnings data for CASI Pharmaceuticals F...
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS PR Newswire BEIJING , March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing a...
2024-03-19 08:19:47 ET More on Fusion Pharmaceuticals Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook Biggest stock movers today: FUSN, NCMI, crypto stocks and more AstraZeneca will buy Fusion Pharmaceuticals for ~$2B Seeking Alpha’s ...
2024-03-08 10:00:23 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...
2024-03-06 08:24:28 ET More on Pre-market losers & stocks. Datasea jumps 23% as subsidiary enters a potential $30M sale agreement Seeking Alpha’s Quant Rating on BeyondSpring Historical earnings data for BeyondSpring Financial information for Beyon...
2024-03-05 08:46:46 ET CASI Pharmaceuticals ( Nasdaq: CASI ) shares rose 25% at $6.36 after company and BioInvent International AB ( BINV ) announced preliminary encouraging data for BI-1206 in combination with rituximab in patients with relapsed/refractory indolent Non-Hodgki...
2024-03-05 07:49:55 ET DENVER, Colo., Mar 05, 2024 ( 247marketnews.com )- CASI Pharmaceuticals, Inc. (NASDAQ: CASI ) and BioInvent International AB (Nasdaq Stockholm: BINV) announced, this morning, initial efficacy data for BI-1206, a first-in-class fully human monoclonal antibody (...
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China PR Newswire BEIJING and LUND, Sweden , March 5, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq...
2024-02-25 12:00:00 ET More on AstraZeneca, Bristol-Myers, etc. Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party Eli Lilly: Very Strong Fundamentals, But Market Is Euphoric Phase 3 data for As...
2024-02-18 02:05:00 ET Summary LianBio plans to stop all its operations by the end of 2024 and will distribute a $4.80 dividend/share ($528M) to its shareholders. Yiviva signed a memorandum of understanding with AstraZeneca China for an R&D collaboration at AstraZeneca’...
News, Short Squeeze, Breakout and More Instantly...
CASI Pharmaceuticals Inc. Company Name:
CASI Stock Symbol:
NASDAQ Market:
CASI Pharmaceuticals Inc. Website:
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS PR Newswire BEIJING , March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing a...
CASI Pharmaceuticals Inc (NASDAQ:CASI) and BioInvent International AB announced preliminary efficacy data for BI-1206 in combination...
2024-03-05 07:49:55 ET DENVER, Colo., Mar 05, 2024 ( 247marketnews.com )- CASI Pharmaceuticals, Inc. (NASDAQ: CASI ) and BioInvent International AB (Nasdaq Stockholm: BINV) announced, this morning, initial efficacy data for BI-1206, a first-in-class fully human monoclonal antibody (...